Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria

Background: High density lipoproteins are an heterogeneous population of particles. Two main subpopulations have been identified, one contains Apo A-I and Apo A-II and is denominated LpA-I:A-II and another one contains only Apo A-I and is denominated LpA-I. Aim: To measure the concentrations of thes...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Calvo M,Carlos, Olmos C,Alfonso, Ulloa M,Natalia, Bustos A,Alejandra, Toledo B,Lorena, Durán S,Daniel, Naveas,Rina
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2000
Materias:	Coronary disease Cholesterol Lipoproteins Lipoproteins, HDL cholesterol
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000100002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872000000100002
record_format	dspace
spelling	oai:scielo:S0034-988720000001000022000-05-25Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronariaCalvo M,CarlosOlmos C,AlfonsoUlloa M,NataliaBustos A,AlejandraToledo B,LorenaDurán S,DanielNaveas,Rina Coronary disease Cholesterol Lipoproteins Lipoproteins, HDL cholesterol Background: High density lipoproteins are an heterogeneous population of particles. Two main subpopulations have been identified, one contains Apo A-I and Apo A-II and is denominated LpA-I:A-II and another one contains only Apo A-I and is denominated LpA-I. Aim: To measure the concentrations of these particles in patients with stable coronary artery disease. Patients and Methods: Serum lipids, A-I and B apolipoproteins, LpA-I, LpA-I:A-II and LpB particles were measured in 73 men aged 33 to 82 years with angiographically documented coronary artery disease (CAD) and 33 control subjects aged 39 to 76 years. LpA-I, LpA-I:A-II and LpB were measured by a noncompetitive enzyme linked immunoassay using previously characterized monoclonal antibodies against ApoA-I, ApoA-II and apoB. Results: Patients with CAD had significantly higher mean levels of LDL cholesterol than the control group (p= 0.038). The mean concentration of LpA-I particles in patients with CAD was significantly lower (p= 0.031) than in control subjects, while the concentration of LpA-I:A-II particles was significantly higher (p=0.016). The percentage of coronary stenosis correlated negatively with LpA-I and positively with LpA-I:A-II. The best relative risk (RR) indicator in these patients was LDL-cholesterol. The relative risk increases 2.5 fold when LpA-I falls below the cut-off level. Likewise, the relative risk increases 3-fold when LpA-I:A-II raises over the cut-off level. Conclusions: Our findings indicate that the quantification of LpA-I and LpA-I:A-II particles might allow a more accurate evaluation of the CAD risk than HDL cholesterol. LpA-I might represent the antiatherogenic fraction of HDL. (Rev Méd Chile 2000; 128: 9-16)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.1 20002000-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000100002es10.4067/S0034-98872000000100002
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Coronary disease Cholesterol Lipoproteins Lipoproteins, HDL cholesterol
spellingShingle	Coronary disease Cholesterol Lipoproteins Lipoproteins, HDL cholesterol Calvo M,Carlos Olmos C,Alfonso Ulloa M,Natalia Bustos A,Alejandra Toledo B,Lorena Durán S,Daniel Naveas,Rina Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
description	Background: High density lipoproteins are an heterogeneous population of particles. Two main subpopulations have been identified, one contains Apo A-I and Apo A-II and is denominated LpA-I:A-II and another one contains only Apo A-I and is denominated LpA-I. Aim: To measure the concentrations of these particles in patients with stable coronary artery disease. Patients and Methods: Serum lipids, A-I and B apolipoproteins, LpA-I, LpA-I:A-II and LpB particles were measured in 73 men aged 33 to 82 years with angiographically documented coronary artery disease (CAD) and 33 control subjects aged 39 to 76 years. LpA-I, LpA-I:A-II and LpB were measured by a noncompetitive enzyme linked immunoassay using previously characterized monoclonal antibodies against ApoA-I, ApoA-II and apoB. Results: Patients with CAD had significantly higher mean levels of LDL cholesterol than the control group (p= 0.038). The mean concentration of LpA-I particles in patients with CAD was significantly lower (p= 0.031) than in control subjects, while the concentration of LpA-I:A-II particles was significantly higher (p=0.016). The percentage of coronary stenosis correlated negatively with LpA-I and positively with LpA-I:A-II. The best relative risk (RR) indicator in these patients was LDL-cholesterol. The relative risk increases 2.5 fold when LpA-I falls below the cut-off level. Likewise, the relative risk increases 3-fold when LpA-I:A-II raises over the cut-off level. Conclusions: Our findings indicate that the quantification of LpA-I and LpA-I:A-II particles might allow a more accurate evaluation of the CAD risk than HDL cholesterol. LpA-I might represent the antiatherogenic fraction of HDL. (Rev Méd Chile 2000; 128: 9-16)
author	Calvo M,Carlos Olmos C,Alfonso Ulloa M,Natalia Bustos A,Alejandra Toledo B,Lorena Durán S,Daniel Naveas,Rina
author_facet	Calvo M,Carlos Olmos C,Alfonso Ulloa M,Natalia Bustos A,Alejandra Toledo B,Lorena Durán S,Daniel Naveas,Rina
author_sort	Calvo M,Carlos
title	Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
title_short	Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
title_full	Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
title_fullStr	Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
title_full_unstemmed	Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria
title_sort	partículas lipoproteicas lpa-i, lpa-i: a-ii y lpb en enfermedad coronaria
publisher	Sociedad Médica de Santiago
publishDate	2000
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000000100002
work_keys_str_mv	AT calvomcarlos particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT olmoscalfonso particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT ulloamnatalia particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT bustosaalejandra particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT toledoblorena particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT duransdaniel particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria AT naveasrina particulaslipoproteicaslpailpaiaiiylpbenenfermedadcoronaria
_version_	1718435898005127168

Partículas lipoproteicas LpA-I, LpA-I: A-II y LpB en enfermedad coronaria

Ejemplares similares